edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Cantargia
Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme; the most advanced indications are non-small cell lung cancer and pancreatic cancer. CAN10, the company’s second lead asset, is being developed for autoimmune diseases. In this video, Cantargia’s chief executive officer Göran Forsberg provides an update on the recently announced rights issue and key clinical highlights.
Get access to the very latest content matched to your personal investment style.